Exicure, Inc. (NASDAQ:XCUR – Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 164,900 shares, a decline of 39.9% from the May 31st total of 274,300 shares. Approximately 3.7% of the company’s shares are sold short. Based on an average daily trading volume, of 299,100 shares, the short-interest ratio is currently 0.6 days.
Exicure Price Performance
Shares of XCUR stock opened at $0.32 on Friday. The business has a 50-day moving average of $0.43 and a 200 day moving average of $0.55. Exicure has a 1-year low of $0.30 and a 1-year high of $1.50. The stock has a market capitalization of $2.77 million, a PE ratio of -0.21 and a beta of 1.28.
Exicure (NASDAQ:XCUR – Get Free Report) last released its quarterly earnings data on Thursday, May 16th. The company reported ($0.61) earnings per share for the quarter.
Exicure Company Profile
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
See Also
- Five stocks we like better than Exicure
- Insider Trades May Not Tell You What You Think
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- MarketBeat Week in Review – 6/24 – 6/28
- What Are Dividend Champions? How to Invest in the Champions
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
